Survival and progostic factors in resected IIIA-N2 non-small cell lung cancer: A study of 288 cases

Chinese Journal of Lung Cancer

Volumn 12, Issue 6, 2009, Pages 587-591

  Lin, Yongbin ^a,b   Liang, Ying ^a,b   Lin, Peng ^a,b   Zhu, Zhihua ^a,b   Zhang, Xu ^a,b   Fu, Jianhua ^a,b   Zhang, Lanjun ^a,b   Long, Hao ^a,b   Wang, Siyu ^a,b   Zeng, Canguang ^a,b   Rong, Tiehua ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PROGNOSIS; SMOKING; SURGICAL APPROACH;

EID: 67650555774     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest, 1997, 111(6):1710-1717
2. Sekine I, Nishiwaki Y, Yokose T, et al. Young lung cancer patients in Japan: diferent characteristics between the sexes[ J]. Ann ThoFac Surg, 1999, 67: 1451-1455
3. Izbicki JR, Passlick B, Karg O, et al. Impact of radical systemic mediastinal lymphadenectomy on tumor staging in lung cancer[ J]. Ann Thorac Surg, 1995, 59(1): 209-214
4. Izbicki JR, Passlick B, Karg O, et al. Efectiveness of radical systemic mediastinal lymphadenectomy in patients with respectable non-small cell lung cancer[ J]. Ann Surg, 1998, 227(1): 138-144.
5. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases[ J]. Ann Thorac Surg, 1997, 63(5): 1441-1450.
6. Andre F, Grunenwald D, Pignon J-P, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a sub classification and implications[ J]. J Clin Oncol, 2000, 18(16): 2981-2989.
7. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4): 351-360
8. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-727
9. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage III B/IV non small-cell lung cancer[ J]. J Clin Oncol, 2002, 20(5) : 1335-1343.